Pacific Edge at risk of losing ‘significant’ revenue stream

Pacific Edge at risk of losing ‘significant’ revenue stream
The test has been used more than 10,000 times since it was first approved in 2020. (Image: Pacific Edge)
Dan Brunskill
Pacific Edge could have its cancer tests dropped by a major US health insurance company which is considering a new way to choose which tests are covered.  Medicare provider Novitas currently reimburses the use of Cxbladder but would not under a new process it has proposed. Currently, the health insurer reviews clinical evidence for each individual product but has proposed relying on third-party lists instead. Pacific Edge said if the proposal was adopted, Cxbladder would no longer receive reimbursement from Novitas, which makes up &ld...

More Markets

International winds of uncertainty blow over NZ sharemarket
Markets Market Close

International winds of uncertainty blow over NZ sharemarket

Markets enter a quiet period after the reporting season. 

Infratil's renewables stake drops by US$133m
Markets

Infratil's renewables stake drops by US$133m

Infratil provided updated valuations on three investments.

John Anthony 07 Mar 2025
NZME board spill support builds towards 50%
Markets

NZME board spill support builds towards 50%

An update to the NZX says more shareholders are expressing support for board changes.

Pattrick Smellie 07 Mar 2025
Tech titans eye NZ's new golden visas
Policy

Tech titans eye NZ's new golden visas

Investors with tens of millions were 'priced out of the market'. Not any more.